Condition: Non Small Cell Lung Cancer · Advanced Solid Tumor · Hematologic Malignancy · Sponsor: Shenzhen TargetRx Co., Ltd.
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
This description comes directly from the study's public registry record.
Hongming Pan, MD · 86-0571-86006926 · panhongming@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06484816